Biotech News

Acrivon Reports Third Quarter 2026 Financial Results and Business Highlights

Acrivon Therapeutics (ACRV)Acrivon TherapeuticsEarnings

Immunology and inflammation (I&I) established as a second strategic pillar for company which is particularly well-suited for its AP3 precision medicine approach AI-driven AP3 platform was used for profiling against approved JAK inhibitors to identify recently acquired ACR-525, a Phase 2-ready,

Related news

Acrivon Therapeutics

Generative Phosphoproteomics Platform Acrivon Therapeutics uses its AP3 platform to measure drug-regulated signaling inside intact cells and identify tumors most likely to respond to specific medicines. ACR-368 ACR-368 is a CHK1/2 inhibitor in a registrational-intent Phase 2b study, with increasing focus on serous endometrial cancer and...

Recent company news

Stock data

Close
1.40 USD
Market cap
67.2M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States